Vaccination reduces central nervous system IL-1β and memory deficits after COVID-19 in mice.
Abigail VanderheidenJeremy D HillXiaoping JiangBen DeppenGayan BamunuarachchiNadia SoudaniAstha JoshiMatthew D CainAdrianus C M BoonRobyn S KleinPublished in: Nature immunology (2024)
Up to 25% of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit postacute cognitive sequelae. Although millions of cases of coronavirus disease 2019 (COVID-19)-mediated memory dysfunction are accumulating worldwide, the underlying mechanisms and how vaccination lowers risk are unknown. Interleukin-1 (IL-1), a key component of innate immune defense against SARS-CoV-2 infection, is elevated in the hippocampi of individuals with COVID-19. Here we show that intranasal infection of C57BL/6J mice with SARS-CoV-2 Beta variant leads to central nervous system infiltration of Ly6C hi monocytes and microglial activation. Accordingly, SARS-CoV-2, but not H1N1 influenza virus, increases levels of brain IL-1β and induces persistent IL-1R1-mediated loss of hippocampal neurogenesis, which promotes postacute cognitive deficits. Vaccination with a low dose of adenoviral-vectored spike protein prevents hippocampal production of IL-1β during breakthrough SARS-CoV-2 infection, loss of neurogenesis and subsequent memory deficits. Our study identifies IL-1β as one potential mechanism driving SARS-CoV-2-induced cognitive impairment in a new mouse model that is prevented by vaccination.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- low dose
- mouse model
- innate immune
- cognitive impairment
- working memory
- traumatic brain injury
- cerebral ischemia
- oxidative stress
- metabolic syndrome
- endothelial cells
- multiple sclerosis
- brain injury
- immune response
- spinal cord
- skeletal muscle
- blood brain barrier
- lipopolysaccharide induced
- human health